SR One

Investor type Corporate Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 167
Average round size
The average size of a deal this fund participated in
Portfolio companies 94
Rounds per year 4.51
Lead investments 33
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 48
Key employees 5

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

SR One appeared to be the VC, which was created in 1985. The company was established in North America in United States. SR One appeared to be a CVC structure as part of the corporation. The leading representative office of defined VC is situated in the Cambridge.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the SR One, startups are often financed by Roche Venture Fund, OrbiMed, Sofinnova Partners. The meaningful sponsors for the fund in investment in the same round are Polaris Partners, M Ventures, Lilly Ventures. In the next rounds fund is usually obtained by Novartis Venture Fund, Pfizer Venture Investments, Roche Venture Fund.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Algeta, Alios BioPharma, Addex Therapeutics. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Biopharma, Medical Device. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

This SR One works on 3 percentage points less the average amount of lead investments comparing to the other organizations. The increased amount of exits for fund were in 2014. The usual things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2015. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. The real fund results show that this VC is 9 percentage points more often commits exit comparing to other companies.

We also calculated 5 valuable employees in our database.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
CM CIC Investissement France, Lille, Nord-Pas-de-Calais
Gooddays Holdings Japan, Tokyo
Huanyu Jiuzhou China, Guangdong, Guangzhou
Nike+ Fuel Lab California, San Francisco, United States
Norrland Fund -
Ophir Equity Partners Seoul, Seoul-t'ukpyolsi, South Korea
Orient Assets Management Beijing, Beijing, China
Samunnati Chennai, India, Tamil Nadu
Shishang Ziben Beilun, China, Zhejiang
Vector Capital California, San Francisco, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Simcha Therapeutics

Life Science
$40M27 Jan 2022 New Haven, Connecticut, United States

nplex biosciences

Health Diagnostics
Market Research
$17M08 Dec 2021 Montreal, Quebec, Canada

Odyssey Therapeutics

Health Care
$218M07 Dec 2021 Cambridge, Massachusetts, United States

HotSpot Therapeutics

Health Care
Life Science
$100M29 Nov 2021 Cambridge, Massachusetts, United States

ADARx Pharmaceuticals

Health Care
$75M08 Sep 2021 San Diego, California, United States

ARS Pharmaceuticals

Health Care
$55M31 Aug 2021 San Diego, California, United States

Effector Therapeutics

Health Care
$60M26 Aug 2021 San Diego, California, United States


Drug Discovery
Health Care
Health Diagnostics
Medical Device
$92M27 May 2021 London, England, United Kingdom


Health Care
$115M13 Apr 2021 Maryland, United States
ADARx Raises $75 Million to Advance Growing Pipeline

– ADARx Pharmaceuticals, Inc. completed a $75m Series B financing.
– The round was co-led by SR One Capital Management and OrbiMed Advisors.
Sirona Capital joined this financing as well as existing investor Lilly Asia Ventures.
– The proceeds from the Series B financing will be used to advance ADARx’s proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery.
– The proceeds will also be used to transition ADARx’s growing pipeline of research phase products into the clinic including initiation of a Phase 1 clinical trial for ADARx’s lead program.

ARS Pharmaceuticals Raises $55M in Series D Funding

– ARS Pharmaceuticals, a San Diego CA-based pharmaceutical company, raised $55M in Series D funding.
– The round was led by SR One with participation from RA Capital Management and Deerfield Management.
– The company intends to use the funds to advance Neffy through approval, to support initial launch activities, and to evaluate it in clinical studies for additional indications.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent SR One?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: